Board of Directors

Mr. Tuomo Pätsi is a Non-Executive Chairman of Faron Pharmaceuticals Ltd., a role he has served since April 2024 prior joining the Board in March 2023 as a Non-Executive Director. Mr. Pätsi is an experienced biotech and pharmaceutical executive with over 30 years of experience in senior management roles in leading global biopharma companies. Mr. Tuomo Pätsi was the President of International Operations and President of the EMEA region and Worldwide Markets for Celgene Corporation, a global pharmaceutical company and currently wholly owned subsidiary of Bristol Myers Squibb, engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer.  Until recently he served as the Executive Vice President for Seagen Inc., a US-based cancer-focused biotechnology company.

Relevant work experience 

• Rigi-Therapeutics AG, Co-Founder 2023-
• Seagen Inc., Executive Vice President, 2020–2022
• Celgene Corporation, President of European and International Operations and President of the EMEA region and Worldwide Markets, 2012–2020
• Human Genome Science, Vice President of Europe 2010–2012
• Amgen Inc., Various positions 1995–2006

Positions of trust 

• Aurealis Therapeutics AG, a Non-Executive Director, 2024-
• Phi Pharma SA, a Non-Executive Director, Chairman, 2024-
• Psyon Games Ltd., a Non-Executive Director, 2023-
• Aqsens Health Ltd., a Non-Executive Director, 2023-
• Notable Labs Inc, a Non-Executive Director, Chairman, 2023-2024

Independence 

Independent of the company and its major shareholders. 

Shareholdings 

31,765 shares and 130,000 stock options, entitling to same amount of shares in the company. 

Between 1996 and 2002, Dr. Markku Jalkanen was the founding CEO and President of BioTie Therapies Corp, which became the first publicly traded Finnish biotech company to be listed on NASDAQ. BioTie was sold to Acorda Therapeutics in January 2016 for $363 million.  

Dr. Jalkanen obtained a Masters in Medical Biochemistry from the University of Kuopio and subsequently received a Ph.D. in Medical Biochemistry from the University of Turku. He completed a side-laudatur examination in Molecular Biology from the University of Turku and completed his post-doctoral training at Stanford University, California between 1983 and 1986.  

Relevant work experience 

• Faron Pharmaceuticals Oy, CEO, 2007–2024
  
• BioTie Therapies Corp, CEO & President, 1996-2002
• Professor, University of Turku, 1992– 
• Docent in Molecular and Cell Biology, University of Turku, 1992– 

Positions of trust 

• Faron Ventures Oy, Board Member
• Inveni Capital, Advisor
• Inveni Capital Management, Board Member
• Meddia Ltd, Board Member
• Priaxon AG, Board Membe

Independence 

Dependent of the company and its major shareholders. 

Shareholdings 

3,413,434 shares (directly and with his spouse) and 540,000 stock options, entitling to same amount of shares in the company. 

Mr. John Poulos served as Vice President, Head of Business Development and Acquisitions for AbbVie from 2013 until 2016. He was also Group Vice President, Head of Pharmaceutical Licensing and Acquisitions for Abbott from 2005 until 2012. During his career with AbbVie and Abbott, Mr. Poulos was instrumental in the negotiation of numerous acquisitions, including Knoll/BASF Pharma (Humira) in 2001 for $6.9 billion, Kos Pharmaceuticals in 2006 for $3.7 billion, Solvay in 2010 for $6.2 billion and Pharmacyclics (Imbruvica) in 2015 for $21 billion. 

Mr. Poulos holds a B.S. in Marketing and MBA in Finance from Indiana University. 

Relevant work experience 

• GNK Advisors Inc., President, 2016- 
• AbbVie, Vice President, Head of Business Development and Acquisitions, 2013-2016 
• Abbott, Group Vice President, Head of Pharmaceutical Licensing and Acquisitions, 2005-2012 

Positions of trust 

• Memgen, Inc., Member of the Board, 2020- 

Independence 

Independent of the company and its major shareholders.

Shareholdings 

No shareholdings and 170,000 stock options, entitling to same amount of shares in the company.  

Dr. Marie-Louise Fjällskog is a professional with extensive experience in the pharmaceutical and biopharmaceutical industry, particularly in the field of clinical oncology, translational research, and drug development.  

With over 25 years of clinical experience, Dr. Fjällskog has made significant contributions to the development of targeted therapies for cancer. She has held key roles in various pharmaceutical companies. She also played an instrumental role in the success of Sensei’s $152 million IPO in 2021. 

She holds an MD degree and a Ph.D. from Uppsala University, Sweden. 

Relevant work experience 

• Faron Pharmaceuticals, Chief Medical Officer 2022-2023
  
• Associate Professor of Oncology, Uppsala University, Sweden 2008- 
• Sensei Biotherapeutics, Chief Medical Officer 2020–2021 
• Merus, VP, Clinical Development 2019–2020 
• Infinity Pharmaceuticals, position 2018–2019 

Positions of trust 

• Biovica International AB, Board Member 2020– 
• Lytix Biopharma, Board Member 2021– 

Independence 

Dependent of the company. Independent of the major shareholders. 

Shareholdings 

No shareholdings and 210,000 stock options, entitling her to the same number of shares in the company. 

Ms. Christine Roth is a pharmaceutical executive with over three decades of experience in the industry. She has played key roles in the development and launch of several therapies, including the first immune-oncology therapy and intentionally designed targeted therapy combinations. Ms. Roth’s expertise extends across various therapy areas, including Oncology, Cardiovascular, Metabolic, and Infectious Diseases. Her career includes leadership positions at major pharmaceutical companies. She holds a bachelor’s degree in chemistry from the University of North Carolina at Chapel Hill. 

Relevant work experience 

• Bayer AG, Head of Global Product Strategy and Commercialization 
• Bayer AG, Executive Vice President of the Oncology Strategic Business Unit 2022-2024 
• GSK, SVP Global Oncology Therapy Area 
• Novartis, VP, 2015-2017 
• Bristol-Myers Squibb, Director, 2008-2009 
• GlaxoSmithKline (GSK), US Commercialization Lead, VP, 2010-2015 

Positions of trust 

• American Society of Clinical Oncology, title
• American Society of Hematology, title

Independence 

Independent of the company and its major shareholders. 

Shareholdings 

46,075 shares and 60,000 stock options, entitling her to the same number of shares in the company. 

Colin Bond has extensive international experience in the CDMO and biopharma industries. Most recently, Colin served as the Chief Financial Officer of Sandoz, listed on the SIX Swiss Exchange, where Colin played a pivotal role in the successful spin-off from Novartis.

Colin is a Fellow of the Institute of Chartered Accountants in England and Wales and a Member of the Royal Pharmaceutical Society of Great Britain. Colin holds a BSc in Pharmacy from Aston University and an MBA from London Business School.

Relevant work experience 

• Sandoz, Chief Financial Officer
• Vifor Pharma, Chief Financial Officer
• Evotec, Chief Financial Officer
• Earlier in Colin’s career, Colin worked as a pharmacist, auditor, and management consultant for Procter & Gamble, Arthur Andersen, and PwC.

Positions of trust 

• BioPharma Credit PLC, Chair of the Audit Committee 
• Formycon AG, Member of the Supervisory Board
• Agomab Therapeutics NV, Non-Executive Director
• Oxford Biomedica PLC, Non-Executive Director
• Siegfried AG, Chair of the Audit Committee 2013-2023

Independence 

Independent of the company. Independent of the major shareholders. 

Shareholdings 

No shareholdings and no stock options in the company. 

Dr. Juho Jalkanen is an experienced biopharmaceutical industry executive with extensive leadership experience across key functional areas including operations, business development, clinical development, medical and regulatory affairs.   

Dr. Jalkanen earned a Master´s degree in economics and business administration from the Turku School of Economics and both his M.D. and Ph.D. degrees from the University of Turku. He is a fully licensed general practitioner and specialist in vascular surgery. 

Relevant work experience 

• Faron Pharmaceuticals, CEO, 2024- 
• Faron Pharmaceuticals, COO, 2022-2024 
• Faron Pharmaceuticals, CDO 2018-2022 
• Faron Pharmaceuticals, Vice President, Business Development 2017-2018 

Positions of trust 

• Faron Pharmaceuticals, Member of the Board, 2025– 
• Faron Pharmaceuticals, Member of the Board, 2013–2018 

Shareholdings 

1,089,888 shares and 567,040 stock options, entitling to same amount of shares in the company.